Document Detail


Immunogenic cell death biomarkers HMGB1, RAGE and DNAse indicate response to radioembolisation therapy and prognosis in colorectal cancer patients.
MedLine Citation:
PMID:  23047645     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Radioembolisation Therapy (RE) is an efficient locoregional treatment for liver metastases from colorectal cancer. Serum biomarkers involved in immunogenic cell death are potentially valuable for early predicting therapy response and estimating prognosis. In a prospective oberservation study, blood samples were taken from 49 consecutive colorectal cancer patients with extensive hepatic metastases before, 24 and 48 hours after RE. Serum levels of high mobility group box 1 (HMGB1), receptor of glycation end products (RAGE) and activity of desoxyribonuclease were compared with response to therapy regularly determined radiologically three months after therapy and with overall survival. Serum levels of HMGB1 were increased already 24h after RE while RAGE levels were decreased and DNAse remained unchanged. In radiological staging, 35 patients demonstrated disease progression while 14 patients had stable disease or remission. Serum HMGB1 levels 24 hours after RE were significantly higher in progressive than in non-progressive patients while for RAGE and DNAse no difference was observed between the response groups. Concerning overall survival, high pretherapeutic (0h) and 24 hours levels of HMGB1 were associated with poor outcome. Multivariate analysis including, HMGB1, tumor, liver and inflammation markers revealed HMGB1 and CRP as independent prognostic parameters. HMGB1 is a valuable serum biomarker for early estimation of therapy response and prognosis in colorectal cancer patients with liver metastases undergoing RE therapy. © 2012 Wiley Periodicals, Inc.
Authors:
Yvonne Nadine Fahmueller; Dorothea Nagel; Ralf-Thorsten Hoffmann; Klaus Tatsch; Tobias Jakobs; Petra Stieber; Stefan Holdenrieder
Related Documents :
23780885 - Intratumoral vessel density as prognostic factors in head and neck squamous cell carcin...
11240785 - Malignant mixed müllerian tumors of the ovary: histopathologic and clinical review of ...
22993585 - Overexpression of endoglin (cd105) is associated with recurrence in radically resected ...
23616135 - Does hürthle cell carcinoma of the thyroid have a poorer prognosis than ordinary folli...
1693315 - The potential for adjuvant therapy in early-stage cervical cancer.
2240175 - Gamma knife: hydrocephalus as a complication of stereotactic radiosurgical treatment of...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-10
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  -     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 UICC.
Affiliation:
Institute of Clinical Chemistry, University-Hospital Munich-Grosshadern, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Keeping Time Under the Midnight Sun: Behavioral and Plasma Melatonin Profiles of Free-Living Lapland...
Next Document:  Combat-Related PTSD Nightmares and Imagery Rehearsal: Nightmare Characteristics and Relation to Trea...